In a significant development for the South Korean healthcare landscape, Seegene has recently unveiled a specialized polymerase chain reaction (PCR) test that is poised to enhance diagnostic capabilities in the region. This innovation comes at a time when the South Korean PCR systems market is projected to experience a compound annual growth rate (CAGR) of 5% through 2033, as reported by GlobalData.
Seegene’s Advanced Diagnostic Tool
The newly launched Novaplex Mpox PCR test assays represent a leap forward in molecular diagnostics, employing multiplex PCR technology to simultaneously detect various pathogens associated with Orthopoxviruses, including the Mpox virus Clades 1 and 2. This capability is particularly crucial given the virus’s incubation period, which can extend up to 21 days.
By utilizing Seegene’s Digitalized Development System (SGDDS), the assay not only boasts high sensitivity but also enables the early differentiation of Mpox, thereby facilitating timely clinical responses. This advancement underscores Seegene’s commitment to enhancing public health through innovative diagnostic solutions.
As of 2024, South Korea is anticipated to account for approximately 6% of the Asia-Pacific PCR systems market, highlighting its pivotal role in the region’s healthcare advancements. The introduction of such specialized testing tools is expected to further solidify the country’s position in the global healthcare arena.
With these developments, the future of PCR testing in South Korea looks promising, paving the way for improved disease detection and management strategies.
